Value for money?

A recent report compared the costs of newer anti-diabetic medications.  This included glitazones, exenatide and gliptins.  The cheapest of these costs about £400 a year per patient compared with under £10 for a sulphonylurea and under £20 for metformin.

The two important questions are :

1.  Are the newer medications 20 times as good as metformin?
2.  Is it better, purely on a cost basis, to treat twenty people with metformin or one person with a gliptin?


Related Articles

8th June 2011

Landmark or Street Clutter?

Time was when only truly momentous trials such as DCCT were described as landmark.  Now the term has become debased to...

Read More

9th January 2018

University Feedback

Are you on one of our courses that is accredited with Teesside University? Would you like to share feedback with the...

Read More

14th March 2013

Think Differently

This was the title of a one day conference held to publicise the new anti-diabetic drug, dapagliflozin.  Quite a good...

Read More